Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment

Inclusion Criteria: * HCV RNA \>= 10\^3 IU/ml at screening * Chronic HCV infection, defined as positive HCV antibody and/or HCV RNA more than 6 months prior to screening * HCV Genotype 1, 2, 3, 4, 5 or 6 * Otherwise eligible for lung transplant at study site Exclusion Criteria: * Age \<18 * Treatment with any of the following agents: * Amiodarone. Subjects previously treated with amiodarone must have stopped the amiodarone at least 60 days prior to day 1 SOF/VEL * Carbamazepine, phenytoin, phenobarbital, oxcarbazepine * Rifabutin, rifampin or rifapentine * HIV regimens containing tenofovir or tipranavir/ritonavir * St John's wort * PPIs, including: Omeprazole, pantoprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole * Modafinil * Have any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with subject treatment, assessment or compliance * Hepatitis B surface antigen positive * History of hepatic encephalopathy or variceal hemorrhage * Abnormal hematological and biochemical parameters, including: * Hemoglobin \<8g/dL * Platelets \<= 50,000/mm\^3 * ALT (alanine aminotransferase), AST (aspartase aminotransferase) or alkaline phosphatase \>=10 times ULN * Total bilirubin \>3mg/dL * Severe renal impairment, ie creatinine clearance (CrCl) \<30mL/min * Pregnant women or women planning to become pregnant * Women or are breastfeeding * Active or recent history (\<=1 year) of drug or alcohol abuse